- Home
- JDZG vs OTLK Comparison
JDZG vs OTLK Comparison
Compare JDZG & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | JDZG | OTLK |
|---|---|---|
| Founded | 2020 | 2010 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 42.5M | 38.7M |
| IPO Year | 2024 | 2016 |
Fundamental Metrics
Financial Performance| Metric | JDZG | OTLK |
|---|---|---|
| Price | $1.71 | $0.53 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $3.83 |
| AVG Volume (30 Days) | 413.3K | ★ 12.7M |
| Earning Date | 12-17-2025 | 02-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,680,742.00 | $1,413,535.00 |
| Revenue This Year | N/A | $1,578.49 |
| Revenue Next Year | N/A | $153.58 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 13.19 | N/A |
| 52 Week Low | $0.73 | $0.50 |
| 52 Week High | $7.92 | $3.39 |
Technical Indicators
Market Signals| Indicator | JDZG | OTLK |
|---|---|---|
| Relative Strength Index (RSI) | 64.22 | 25.48 |
| Support Level | $1.10 | $0.51 |
| Resistance Level | $1.85 | $0.54 |
| Average True Range (ATR) | 0.24 | 0.05 |
| MACD | 0.11 | 0.01 |
| Stochastic Oscillator | 79.45 | 15.94 |
Price Performance
Historical ComparisonAbout JDZG JIADE LIMITED
Jiade Ltd specializes in providing one-stop comprehensive education supporting services to adult education institutions, through a wide range of software platform and auxiliary solutions. Auxiliary solutions encompass exam administration services and teaching support services throughout the entire teaching cycle. Specifically, the company offers pre-enrollment guidance on school/major selection and application strategy development, training for entrance exams, and assistance in the application process. The company also provides offline tutoring, exam administration services, guidance on graduation thesis, and social practice assistance included in the one-stop comprehensive education supporting services in the People's Republic of China.
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.